Ultimovacs Feed

Land	Norge
Lista	OB Match
Sektor	Hälsovård
Industri	Bioteknik

2021-12-02 19:00:00 Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma +0,37% | 16,8 MNOK

2021-12-02 16:30:00 Ultimovacs ASA: Mandatory notification of trade by primary insider +0,37% | 16,8 MNOK

2021-11-29 20:15:20 Ultimovacs ASA: Mandatory notification of trade by primary insider +0,35% | 4,53 MNOK

2021-11-29 20:15:15 Ultimovacs ASA: Mandatory notification of trade by primary insider +0,35% | 4,53 MNOK

2021-11-25 08:00:00 Ultimovacs ASA: Mandatory notification for close associate +3,02% | 5,05 MNOK

2021-11-11 08:00:00 Ultimovacs ASA: Third quarter 2021 result presentation -0,47% | 12,5 MNOK

2021-11-09 14:00:00 Ultimovacs’ SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma -0,60% | 15,3 MNOK

2021-11-03 08:00:00 Ultimovacs ASA: Invitation to third quarter 2021 results presentation -0,63% | 10,8 MNOK

2021-11-02 10:57:35 Ultimovacs ASA – New share capital registered +0,31% | 8,74 MNOK

2021-11-02 08:35:47 BioStock Studio: Ultimovacs reaches key milestones with UV1 +0,31% | 8,74 MNOK

2021-11-02 08:35:47 BioStock Studio: Ultimovacs når milstolpe med UV1 +0,31% | 8,74 MNOK

2021-10-27 07:37:31 Ultimovacs ASA – Transactions by primary insiders and closely associated parties -4,03% | 305 MNOK

2021-10-27 00:23:44 Ultimovacs ASA - Private placement of new shares successfully placed +2,97% | 10,9 MNOK

2021-10-27 00:06:50 Ultimovacs ASA - Private placement of new shares successfully placed +2,97% | 10,9 MNOK

2021-10-26 16:47:38 Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC) -4,03% | 305 MNOK

2021-10-26 16:31:00 Ultimovacs ASA - Contemplated private placement -4,03% | 305 MNOK

2021-10-26 16:30:00 Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC) -4,03% | 305 MNOK

2021-10-21 08:05:00 Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma +12,58% | 41,7 MNOK

2021-10-21 08:00:00 Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma +12,58% | 41,7 MNOK

2021-10-15 10:51:04 Ultimovacs ASA: New share capital registered -5,82% | 30,3 MNOK

2021-10-13 08:33:58 Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma +14,08% | 44,5 MNOK

2021-10-13 08:00:00 Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma +14,08% | 44,5 MNOK

2021-10-12 18:34:14 Ultimovacs ASA: Share capital increase related to exercise of options +14,08% | 44,5 MNOK

2021-10-08 09:07:18 Ultimovacs ASA announces Two Key Appointments to the Management Team as the Operations Advances +1,34% | 14,4 MNOK

2021-10-08 09:07:13 ULTI: Ultimovacs ASA announces Two Key Appointments to the Management Team as the Operations Advances +1,34% | 14,4 MNOK

2021-10-04 16:21:05 ULTI: Flagging av nedsalg under 5% eierskap -1,62% | 26,5 MNOK

2021-10-01 12:35:00 Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine +10,19% | 50,5 MNOK

2021-10-01 12:30:00 Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine +10,19% | 50,5 MNOK

2021-08-20 08:05:00 Ultimovacs ASA: Second Quarter 2021 Result Presentation +4,54% | 7,08 MNOK

2021-08-20 08:00:00 Ultimovacs ASA: Second quarter 2021 result presentation +4,54% | 7,08 MNOK

2021-08-12 07:50:00 Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma +8,25% | 11,2 MNOK

2021-08-12 07:45:00 Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma +8,25% | 11,2 MNOK

2021-08-11 17:05:00 Ultimovacs ASA: Invitation to Second Quarter 2021 Results Webcast Presentation +8,25% | 11,2 MNOK

2021-08-11 17:00:00 Ultimovacs ASA: Invitation to second quarter 2021 results webcast presentation +8,25% | 11,2 MNOK

2021-08-05 08:05:00 Ultimovacs Announces First Patient Enrolled in Phase II FOCUS Trial of UV1 in Head-and-Neck Cancer -2,54% | 1,11 MNOK

2021-08-05 08:00:00 Ultimovacs announces first patient enrolled in Phase II FOCUS trial of UV1 in head-and-neck cancer -2,54% | 1,11 MNOK

2021-07-05 21:40:09 Ultimovacs Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines -2,67% | 1,31 MNOK

2021-07-05 21:30:00 Ultimovacs’ Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines -2,67% | 1,31 MNOK

2021-06-04 15:12:37 ULTI: Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program +2,59% | 14,9 MNOK

2021-06-04 15:05:00 Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program +2,59% | 14,9 MNOK

2021-06-04 15:00:00 Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program +2,59% | 14,9 MNOK

2021-06-01 14:00:00 Ultimovacs Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma +1,57% | 7,47 MNOK

2021-06-01 08:31:28 ULTI: Ultimovacs Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma +1,57% | 7,47 MNOK

2021-05-28 17:08:03 Ultimovacs ASA: Mandatory notification of trade by primary insider +6,44% | 10,1 MNOK

2021-05-25 17:00:00 Ultimovacs ASA: Mandatory notification of trade by primary insider -2,98% | 7,45 MNOK

2021-05-20 17:00:00 Ultimovacs ASA: Mandatory notification of trade by primary insider +1,83% | 29,9 MNOK

2021-05-19 22:56:08 Ultimovacs’ UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data +7,13% | 27,3 MNOK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

2022-02-17	Bokslutskommuniké 2021
2021-11-11	Kvartalsrapport 2021-Q3
2021-08-20	Kvartalsrapport 2021-Q2
2021-05-11	Kvartalsrapport 2021-Q1
2021-04-22	Ordinarie utdelning ULTI 0.00 NOK
2021-04-21	Årsstämma 2021
2021-02-17	Bokslutskommuniké 2020
2020-11-12	Kvartalsrapport 2020-Q3
2020-11-11	Extra Bolagsstämma 2020
2020-08-21	Kvartalsrapport 2020-Q2
2020-05-14	Kvartalsrapport 2020-Q1
2020-04-16	Ordinarie utdelning ULTI 0.00 NOK
2020-04-15	Årsstämma 2020
2020-02-14	Bokslutskommuniké 2019
2019-11-14	Kvartalsrapport 2019-Q3
2019-08-21	Kvartalsrapport 2019-Q2

Ultimovacs

Beskrivning

Kalender

Ultimovacs

Beskrivning

Kalender

Språk

Typ

År

Språk

Typ

Ett Mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden